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Solid tumour accounts for 90% of all cancers. The current treatment approach for most solid tumours is surgery, however
it is limited to early stage tumours. Other treatment options such as chemotherapy and radiotherapy are non-selective, thus
causing damage to both healthy and cancerous tissue. Past research has focused on understanding tumour cells themselves, and
conventional wisdom has aimed at targeting these cells directly. Recent research has shifted towards understanding the tumour
microenvironment and it’s differences from that of healthy cells/tissues in the body and then to exploit these differences for
treatmeat of the tumour. One such approach is utilizing anaerobic bacteria. Several strains of bacteria have been shown to
selectively colonize in solid tumours, making them valuable tools for selective tumour targeting and destruction. Amongst them,
the anaerobic Clostridium has shown great potential in penetration and colonization of the hypoxic and necrotic areas of the
tumour microenvironment, causing significant oncolysis as well as enabling the delivery of therapeutics directly to the tumour in
situ. Various strategies utilizing Clostridium are currently being investigated, and represent a novel area of emerging cancer therapy.
This review provides an update review of tumour microenvironment as well as summary of the progresses and current status of
Clostridial spore-based cancer therapies.
1. Introduction
Cancer is currently a major cause of morbidity and mortality
internationally and poses a significant burden on both
patients and their families and the healthcare system as a
whole. Solid tumours, in particular, account for 90% of
all cancers. A solid tumour is composed of a complex mix
of tumour cells and nontumour cells, including supporting
stromal and infiltrating blood cells, immune cells, and
various molecules in proximity to these cells. This collection
of cells and their metabolism is referred to as the tumour
microenvironment. This unique tumour milieu not only
allows for growth and metastasis, but additionally aids in
the resistance of cancer cells to current chemotherapy and
radiotherapy, thereby hindering their success. Consequently,
there is an urgent demand for more suitable and effective
treatment options for those suffering from solid tumours.
2. Tumour Microenvironment
Research in the past has typically focused on understanding
the molecular and genetic aspects of cancer cells, which
led to treatment options geared towards killing the cancer
cells themselves. Recent advances in the field of oncology
have lead to a greater understanding of tumour pathology.
Currently, a greater research emphasis has been placed on
comprehending the unique environment of solid tumours,
referred to as the tumour microenvironment. Developments
in this field have lead to the possibility of pursuing methods
of treatment which serve to control this milieu in such a way
that will enable us to manage the growth and metastasis of
the tumour itself. This has generated the potential for new
therapeutic targets and treatment options for cancer patients.
Clostridium-spore-based bacterial therapy is one such a novel
strategy.
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2.1. Angiogenesis. Growth and progression of tumour cells
requires an increased supply of both oxygen and nutrients.
For this the formation of a new vascular network is required
to meet these demands [1]. Under regular physiological
conditions, angiogenesis in cells results in a structurally
well organized and highly efficient network of vasculature.
However, this is not the case in tumours, where angiogenesis
leads to a chaotic network of blood vessels. This is a
distinctive component of the cancer microenvironment.
This vasculature may be characterized by disorganization,
dilation, branching, shunts, and varied diameters which
results in inconsistent blood flow and further alters the
microenvironment by creating hypoxic areas and regions
high in acidity [1, 2]. Angiogenesis is a crucial component in
the metastasis of cancer cells, and if it can be controlled, has
the capability of halting the spread of cancer to other tissues.
Additionally, the chaotic nature of the blood vessel and its
network in the tumour microenvironment poses a problem
for current cancer therapies in that it makes it difficult to
administer drugs uniformly and in effective concentrations
in all areas of the tumour. These are two problems which
are trying to be overcome by instead treating the tumour
environment and controlling angiogenesis as opposed to
killing the cancer cells directly.
The key mediator of angiogenesis is the glycoprotein
vascular endothelial growth factor (VEGF), which stimulates
blood vessel growth by acting on endothelial cells [3].
Additionally, VEGF can afford viability of immature blood
vessels by preventing apoptosis, and evidence has shown it
can also make vasculature more permeable causing leaky cell
walls resulting in an increase of interstitial pressure [4–6].
Mediation by the VEGF proteins is a critical component in
creating the chaotic vasculature of the tumour microenvi-
ronment, and as such is a primary research target for new
therapeutic strategies.
2.2. Hypoxia and HIF-1. Acute and chronic lack of blood
supply resulting in the absence of oxygen and known as
hypoxia is also a definitive characteristic of the tumour
micro milieu and is caused by inefficient blood supply to
cancerous cells. The hypoxic environment poses a challenge
to traditional cancer treatment options in that this oxygen-
depleted environment makes the solid tumour cells less
susceptible to killing with chemotherapy and radiation, less
genetically stable (thus more difficult to predict its response
to treatment), and resistant to apoptosis [7]. Since these
cells are devoid of oxygen, carbohydrate metabolism occurs
via glycolysis resulting in the production of lactic acid and
decreasing the pH of the tumour environment. Critical in
the control of tumour hypoxia are the hypoxia-inducible
factors (HIFs), a family of transcription factors which serve
in the regulation of mammalian response to the absence
of oxygen. One of the targets of HIF-1 is VEGF, which is
switched on in a hypoxic environment. VEGF then stimulates
angiogenesis creating poor vasculature within the tumours,
causing further hypoxia creating a positive feedback loop
where both factors are stimulated. It is important to note
that VEGF is not the only target of HIF-1, and in fact, more
than 60 direct target genes have been identified, many playing
crucial roles in cell survival, metabolism, and metastasis
of cancer cells [8]. The crucial role that HIF transcription
factors have in creating the tumour microenvironment
makes these proteins potentially important cancer treatment
targets.
2.3. Apoptosis and Necrosis. The proinflammatory cytokine
tumour necrosis factor alpha (TNF-α) plays a unique
role in the tumour environment where it permits cellular
communication and is capable of promoting both growth
and necrosis. TNF-α acts in conjunction with many other
molecules within the cell to perform these tasks. For instance,
tumour necrosis is carried out first by endothelial cell
apoptosis caused by deactivation of the integrin avb3 and
disruption of the interface with the extracellular matrix
(ECM), followed by T-cell activation to remove remaining
tumour cells [9, 10]. In a contradictory role to this, in low
chronic doses, TNF-α promotes tumour growth, invasion,
and metastasis. One way it accomplishes this is by the
remodelling of tissue by inducing matrix metalloproteins
(MPPs) [11]. TNF-α also activates nuclear factor-κb (NF-
κb), a transcription factor, which stimulates the proliferation
of tumour cells and regulates antiapoptotic genes, and thus
can protect the cancerous cells from the apoptotic cascade
induced by TNF-α [12]. NF-κb has also hindered some forms
of cancer treatment involving cytokines, chemotherapeutics,
and radiation which have all been shown to activate NF-κb,
helping to prevent apoptosis [13]. Both TNF-α and NF-κb
can both be targets for future cancer therapies; TNF-α can be
triggered to induce apoptosis, and NF-κb can be inhibited to
prevent tumour growth and spread, as well as aid in making
solid tumour cells more susceptible to apoptosis by treatment
with other therapeutic cancer agents.
2.4. Tumour Structure and Stromal and Interstitial Pressure.
Tumour structure greatly contributes to the microenviron-
ment of cancer. The membrane structure, in particular,
is an essential part of tumour invasion and metastasis.
The extracellular matrix (ECM) is a key component to
the tumour structure, and it comprises molecules essential
to cell signalling [14]. Structural components of the ECM
include fibrous elements, link proteins (fibronectin for
example), and space-filling molecules, whereas the signalling
components comprise the cytokines, growth factors, ions,
and peptides [14]. Fibronectins, one of the most abundant
structural proteins of the ECM, have additional functions
in tumour cells aside from their structural roles and aid
in regulation of adhesion, migration, differentiation, and
proliferation [15]. Fibronectins can also serve in signalling
as solid-phase ligands, further adding to the complexity of
the tumour micro milieu [16]. Another set of structural
components of the ECM that duals as signalling molecules
are collagens. In solid tumours, collagen has sometimes
shown to be upregulated, providing a rigid matrix aiding
in cell growth. The primary role of collagen, however, is in
anchoring cells to the membrane and aiding in regulation
[17]. As such, both fibronectin and collagen are key regu-
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lators of tumour invasion, metastasis, growth, proliferation,
and signalling.
Additional regulators of structural elements of the
tumour cell are essential in metastasis. For example, the steps
involved in the spread of cancer between tissues include the
degradation of basement membrane and ECM, modulation
of cell adhesion molecules, followed by migration to adjacent
tissue [18]. During degradation of the basement membrane
and ECM, matrix metalloproteinases (MMPs) play a vital
role. MMPs are a family of enzymes capable of degrading
all parts of the ECM, as well as other nonmatrix substrates
which also contribute to the tumour microenvironment
and progression [19–21]. MMPs also play a crucial role
in angiogenesis, where they degrade the cellular matrix
surrounding endothelial cells making them a target for
antiangiogenesis [18, 22]. Research has shown them to be
involved in cell growth (both inhibitory and stimulatory),
proliferation, and apoptotic prevention as well [14].
The high interstitial fluid pressure compared to that
of normal cells is yet another key defining element of the
tumour milieu. This is the result of the chaotic vasculature
of solid tumours as previously described, due to high
vessel permeability and cell density outside the vessels, low
lymphatic drainage, and poor perfusion [23]. This causes
problems for the administration of cancer therapeutics,
which may not successfully be able to reach all tissues in
sufficient quantities due to transcapillary transport [24].
2.5. Cancer-Related Inflammation. Inflammation is present
in the microenvironment of some solid tumours prior to
metastasis, and in others, an oncogenic change induces an
inflammatory response which aids in the development of
tumours [25]. This inflammation assists in proliferation,
survival, angiogenesis, and metastasis, while simultaneously
facilitating in avoiding the adaptive immune system, and dis-
rupting signals from hormones and chemotherapeutics [25].
Therefore, molecules which coordinate these inflammatory
responses are important constituents of the tumour micro
milieu. Cytokines and chemokines are two classes of these
regulatory components.
Chemokine is a family of cytokines which play a
vital role in the directing leukocyte migration to sites of
infection and inflammation in the body. In cancer, aberrant
chemokine and cytokine receptor production facilitates
tumour growth by mediating migration of leukocytes to
tumour cells and stimulating the release of growth factors,
such as tumour transforming growth factor (TGF), and
promoting angiogenesis [26]. Cytokines are components
of the immune system which stimulate the generation
of antitumour specific responses. Additionally, however,
cytokines may influence carcinogenesis and metastasis by
modifying the tumour phenotype [27]. A primary example is
interleukin-2 (IL2), a pluripotent cytokine which augments
innate immune responses such as activation of natural killer
and lymphokine-activated killer cells, and neoplastic cell
killing by MHC-restricted T-cell responses [28].
3. The Impact of Tumour Micro Milieu on
Current Cancer Therapy
Thus far, the development of successful cancer therapies
has been hampered by various aspects of the tumour micro
milieu. Primarily, the obstacles of angiogenesis, hypoxia,
and heterogeneous cell arrangement must somehow be
overcome in order to develop viable treatment strategies for
solid tumours. Along with increased efforts to understand
the tumour microenvironment, alternative cancer treatment
strategies have, however, emerged which seek to utilize this
environment to an advantage.
3.1. Selective Tumour Colonization. As previously discussed,
the unique microenvironment of solid tumour cells consists
of a complex, disarrayed set of blood vessels due to tumour
angiogenesis, which leads to hypoxic areas, varying pH, and
inconsistent blood flow. This poses a problem to current
cancer treatment strategies in that therapeutics cannot be
evenly distributed to all tumour tissue in effective concen-
trations, hindering some conventional chemotherapeutics.
Additionally, many anticancer drugs target rapidly dividing
cells and ignore the stromal cells and other cells that make up
a tumour and can often result in tumour regrowth. Hypoxia
in tumour cells may allow for inhibited cell cycle progression
and proliferation, thus rendering these types of treatments
ineffective [29]. In ionizing radiation, DNA damage occurs,
which under aerobic conditions becomes lethal due to
fixation by oxygen. In the anaerobic environment of solid
tumours, however, the DNA can be restored to its original
condition and may remain unharmed [30, 31]. The hypoxia
of the tumour is undesirable for treatment in that it
contributes to a higher degree of malignancy in the cancer
cells, whilst aiding in cell development and angiogenesis
[18]. Severe hypoxia in tumours, not surprisingly, has there-
fore been linked to poor prognosis [32]. Other treatment
strategies have also been rendered less effective due to this
hypoxic environment. The initially very promising area of
utilizing adenoviral vectors to treat cancer was thwarted by
this tumour hypoxia, where it induced halting of G1 cells
responsible for viral replication, resulting in less effective
treatment [33, 34]. The hypoxic milieu negatively influenced
treatment via retroviral vectors due to the phosphorylation
of eIF2α leading to inhibition of translation [35].
Bacterial-based cancer therapy using Clostridium spores
offers a selective advantage in overcoming the obstacles
of hypoxia and necrosis. Clostridium species, being strictly
anaerobic will only colonize in areas devoid of oxygen,
and when systematically injected, spores germinate and
multiply in the hypoxic/necrotic areas of solid tumours
[36]. Clostridium, although anaerobic, possesses the ability
to sporulate, allowing them to remain dormant in envi-
ronments where oxygen is present. However, when growth
conditions are suitable (i.e., in the hypoxic/necrotic milieu of
solid tumours), the Clostridium spores germinate and begin
to colonize these areas. This aspect of Clostridium growth is
being exploited for use in a number of various novel cancer
treatment strategies currently being developed which utilize
4 Journal of Toxicology
Table 1: Summary of current methods being researched in Clostridium-based cancer therapies.
Method Premise Target/drugs
Clostridium
species being
used
Reference
Clostridium
directed enzyme
prodrug therapy
(CDEPT)
Clostridium is genetically engineered to express an enzyme
which cleaves a prodrug into its cytotoxic form.
CD/F-FU
C. sporogenes
C. beijerinckii
C.
acetobutylicum
[39]
[49]
[41]
NTR/CB1954
C. beijerinckii
C. sporogenes
[37]
[40]
NTR/PR-104
Administration of
cytokines/cytotoxic
agents
Clostridium is used to deliver agents (cytokines) to either
act directly cytotoxic to cells or enhance immune system
response to tumour cells.
murine TNFα
C.
acetobutylicum
[41, 50, 51]
IL-2
C.
acetobutylicum
[42]
Clostridium
directed antibody
therapy (CDAT)
Clostridium is modified to produce highly specific
antibodies against tumour antigens.
VHH against HIFα C. novyi-NT [45]
Combined
bacteriolytic
therapy (COBALT)
Clostridium which demonstrate direct antitumour effects
are administered in conjunction with other known cancer
therapies to increase oncolysis.
Clostridium/
mitomycin C and
cytotaxin Clostrid-
ium/vinorelbine or
docetaxel
C. novyi-NT
C. novyi-NT
[47]
[52]
Release of
liposomal
encapsulated drugs
Species of Clostridium which secrete lipid-degrading
enzymes are used for the targeted release of
liposome-encapsulated drugs at the tumour site.
Clostridium/Doxil C. novyi-NT [48]
Clostridium as a vector to deliver therapeutics directly to the
solid tumour site (Table 1). Clostridial vectors can be safely
administered as spores, and their efficacy in delivering and
secreting therapeutic proteins has been demonstrated in a
number of preclinical trials.
3.2. Clostridium-Directed Enzyme Prodrug Therapy. One
novel treatment strategy, known as suicide gene therapy or
gene-directed enzyme prodrug therapy, utilizes an enzyme
which cleaves ormodifies a prodrug such that cleavage results
in the active, oncolytic form of the toxin. Using Clostridium
species as a vector, known as Clostridium directed enzyme
prodrug therapy (CDEPT), the bacterium can be genetically
modified to express these proteins. When spores are admin-
istered systematically, the Clostridium selectively grows and
colonizes in the tumour cells where it expresses the prodrug
cleaving enzyme. When the therapeutic is then administered,
it is only cleaved into its active component in the localized
tumour environment, resulting in tumour cell specificity
as opposed to the nonspecific targeting exhibited by most
other current treatment options, such as radiation. Although
other vector systems exist (primarily viral vectors), bacterial
vectors, Clostridia in particular, convey benefits such as lower
toxicity, higher safety, and nonexistence no restraints on
the gene size to be delivered. Additionally, bacteria can be
rendered inactive rather quickly by the administration of
antibiotics further increasing the safety of these approaches.
Several enzyme/prodrug combinations are currently
available. The cytosine deaminase (CD) and 5-fluorocytosine
(5FC) system was one of the first systems to be cloned
into Clostridium. CD converts the prodrug 5FC into 5-
fluorouracil (5FU), a cytotoxic compound. Another com-
mon combination is the nitroreductase (NT R) enzyme,
which converts CB1954 to a DNA cross-linking agent [37,
38]. Although these enzymes have been successfully cloned
into a number of Clostridium strains, C. sporogenes has
shown the highest potential thus far. Injection of recom-
binant CD expressing C. sporogenes NCIMB10696 spores
into tumour-bearing mice was successful in tumour-specific
expression of CD [39]. Moreover, when this was combined
with its prodrug 5FC, significant tumour growth delay was
achieved. Promising results were also obtained with the
NTR enzyme/Pr-104 prodrug combination as well. NTR was
successfully transformed into and expressed by C. sporogenes,
and in vivo studies where spores were injected into tumour-
bearing mice showed significant tumour reduction [40].
3.3. Clostridium to Enhance the Immune System and Tumour
Cell Recognition. Another novel treatment being developed
in cancer therapy is genetic engineering of bacteria that
express an enzyme possessing direct cytotoxic actions, as
opposed to having prodrug cleaving actions. As previously
discussed, TNF-α, a cytokine, can act as a tumour regressor
in high doses where it functions as a vasculotoxic agent and
as such is being researched as one of these cytotoxic enzymes.
Over a decade ago, Theys et al. [41] genetically engineered
C. acetobutylicum DSM792 to express and secrete murine
TNF-α. Although TNF was secreted and biologically active,
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colonization levels of recombinant C. acetobutylicum were
low, and sufficient amounts of TNF to combat the tumour
cells were not secreted, and therefore no therapeutic benefits
were observed [41]. More recently, an attempt was made
at increasing TNF-α expression and secretion levels in C.
acetobutylicum by adjusting transcription, translation, and
secretion processes; however, no significant advances were
made and TNF-α expression remained constant [42]. For
this protein to be excreted in levels high enough to act as
an antitumour agent, ways must be developed which would
either allow increased TNF-α production at the tumour site
or utilized the synergistic effect of interleukin-2 and TNF-α
[42, 43].
Interleukin-2 (IL-2) is a cytokine which enhances the
immune system’s natural anticancer functions [42]. Admin-
istration of cytokines such as IL-2 to the tumour environ-
ment may stimulate the immune system to discern and assail
the solid tumour cells; however cautionmust be taken as high
systemic levels of IL-2 cause toxicity. This was the basis for
the genetic modification of C. acetobutylicum DSM792 by
Barbe et al. [42] in 2005 to express increased levels of IL-
2. By introducing rat IL-2 into Clostridium, solid tumours
were specifically targeted and sufficient levels of IL2 were
produced and excreted to decrease tumours in mice, while
avoiding the effects of systemic toxicity. It may be possible to
make treatment of this sort more effective by combining with
other cytokines, enzymes, or chemotherapy. Additionally,
by combining IL-2-recombinant Clostridium with a vascular
targeting agent, it is hypothesized that colonization of the
bacteria will increase while also increasing the release of
tumour antigens from cells that have become necrotic, thus
increasing the antitumour response by immune cells [42].
3.4. Clostridium-Directed Antibody Therapy (CDAT).
Another area in which this is being utilized is Clostridium-
directed antibody therapy (CDAT) where Clostridium is
modified to produce high specificity antibodies against
tumour antigens. Recently, CDAT was used to target HIF1α
cells using the variable domain of the heavy-chain subclass
of antibodies (VHH). A VHH against HIF1α, which when
expressed in mammalian cells binds and inhibits HIF activity
[44], was introduced into C. novyi-NT by heterologous gene
transfer. The VHH, when isolated from the Clostridia,
retained its binding capacity and specificity for the target,
and overall the study demonstrated successful conjugation,
expression, and functionality of these antibodies [45].
Further research into codon usage and promoters of the
VHH antibody genemust be performed, however, to increase
expression levels in Clostridia in order to successfully utilize
this method in future cancer therapies. The potential of
this would be in that by targeting HIF1α, hypoxia in the
solid tumour could be controlled, and subsequently, factors
contributing to metastasis and invasion could be eliminated,
thus impeding the spread of the cancerous cells. This type
of treatment would be useful as a combined modality
treatment, where Clostridia spores are administered and
express VHH upon germination. Once VHH minimizes
tumour hypoxia by targeting HIF1α, a second treatment
such as chemotherapy or radiation may be applied, which
would be more effective as a result of the decreased hypoxia.
Our laboratory has recently created a hybrid toxin that
could be expressed and delivered using the clostridial system.
This toxin utilises the high affinity of receptor binding
fragment of Clostridium perfringens enterotoxin (CPE). CPE
naturally binds to CLDN-4 through the C-terminal 30
amino acid. Taking advantage of the fact that CLDN-
4 is overexpressed on a range of cancer cells, we thus
constructed a cDNA comprising C-CPE and a fragment
of exotoxin A(ETA’) (C-CPE-ETA’). The recombinant C-
CPE-ETA’ fusion protein was shown to retain the specificity
of binding to CLDN-4 and initiate rapid penetration into
cytosol in five different CLDN-4-positive cancer cells (MCF7,
A431, SW480, PC3, and DU145) but not to CLDN-4-
negative cells (HELA, HUVEC). C-CPE-ETA’ was strongly
cytotoxic towards CLDN-4-positive cancer cell, as opposed
to cells lacking CLDN-4 expression. Moreover, we have
also demonstrated that the recombinant fusion protein had
significant anticancer ability in CLDN-4-positive cancer
models in vivo. Subcutaneously implantedMCF7 and SW480
xenograft tumours were significantly decreased or abolished
after three repeated injection of the hybrid toxin [46].
3.5. Combined Bacteriolytic Therapy (COBALT). COBALT is
a proposed method of cancer treatment which has been rela-
tively successful thus far. In this type of therapy, a bacterium
is engineered to exhibit antitumour properties, such as pro-
teolytic enzymes, which is then administered in conjunction
with other known cancer therapies to work synergistically
and improve oncolysis. A new strain of Clostridium, C.
novyi-NT, which expresses proteolytic proteins was recently
developed which showed significant antitumour activity in
mice. To identify and manufacture this strain, 26 strains of
bacteria were tested for tumour colonisation efficiency, and
C. novyi was particularly promising. However, this contained
a lethal toxin, which was subsequently genetically removed,
and the newly engineered strain was designated C. novyi-
NT [47]. Systemic administration of C. novyi-NT spores
destroys adjacent cancer cells while simultaneously prompt-
ing inflammatory action by the recruitment of cytokines,
attracting neutrophils, monocytes, and lymphocytes which
attack cancer cells [38]. In an attempt to increase the
antitumour action of the bacteria, spores of this strain were
administered alongside of known anticancer drugs. Very
promising results were obtained when bacterial C. novyi-NT
spores were administered in conjunction with microtubule-
interacting chemotherapeutic agents such as vinorelbine
and docetaxel, and in 2006 a phase 1 clinical trial was
commenced. Unfortunately, the first study was terminated
due to design problems, but a second attempt at a phase
one clinical trial to test safety has recently started and is
still in the stages of recruiting participants [http://www.
clinicaltrials.gov/ct2/results?term=c.novyi-NT]
3.6. Liposome-Mediated Preferential Release of Drugs at Solid
Tumour Site. Genome analysis of C-novyi-NT has demon-
strated that some of its oncolytic capabilities are due to the
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presence of several lipid degrading enzymes, which are highly
expressed when C. novyi-NT is colonised in tumours [31].
In 2006, Cheong et al. [48], exploited this property of C.
novyi-NT to release liposomal drugs within the tumour. It
was hypothesised that since this species lyses red blood cells,
its ability to disrupt membranes might be able to increase
the release of liposome-encapsulated drugs directly at the site
of the tumour. A form of doxorubicin incorporated within
a liposome called Doxil was utilised, and promising results
were obtained. Systemic injection of C. novyi-NT spores
in conjunction with Doxil completely eliminated tumours
in two models. Further analysis of protein fractions of
the culture medium, as well as mass spectroscopy analysis,
revealed that lipase was indeed the protein product secreted
by C. novyi-NT which increased the effectiveness of the
liposome-encapsulated drug. The significance of this study is
that further research can be performed using other liposome
encapsulated drugs with specific targeting and release within
the tumour microenvironment [31, 48].
Although theoretically very promising, there are still
some obstacles that must be overcome in order for Clostrid-
ium-directed therapies to be developed as a viable treatment
option for cancer patients. Clostridium species which are
easily transformable, such as C. acetobutylicum, do not
typically have high colonisation efficiencies, whereas species
which typically colonise well in tumour cells, such as
C. sporogenes, C. oncolyticum, and C. novyi-NT are not
easily transformed. However, recent advancements in genetic
engineering technologies have allowed for improvements
in this area. Using a new method of conjugative transfer
from E. coli, Theys et al. were able to successfully transform
plasmid vectors at higher frequencies into these strains
of Clostridium, opening many new doors in Clostridium-
directed cancer therapies [49]. Keeping this in mind, there
are still many areas which need to be improved before
Clostridium can be successfully implemented in current
cancer therapies, but research efforts continue and advances
are being made regularly in this field.
4. Conclusions and Future Perspectives
Clostridium-based cancer therapy is a promising approach
for the treatment of solid tumours. Recently, understanding
the solid tumour microenvironment and its influence on
cancer therapy has profoundly changed our thinking about
cancer therapy. We have realised that the unique solid
tumour micro milieu has been one of the greatest hindrances
thus far in successful cancer treatment. The utilisation of
anaerobic Clostridium species allows for a targeted and
curative treatment by destroying tumour microenvironment
first, creating opportunity for combinational therapies. In
addition, numerous strategies involving the administra-
tion of Clostridium spores to selectively deliver cancer
therapeutics directly to the site of the solid tumour are
currently being developed, and in many cases, promising
oncolytic capabilities have been demonstrated. However,
successful implementation of this mode of therapy in
clinical trials relies on developmenting and manufacturing
a Clostridium species to have both high colonisation effi-
ciency and expression and excretion of sufficient high levels
of the therapeutic proteins. Improving genetic engineering
methods to genetically modify bacteria and modulation of
gene expression to yield maximum protein secretion are
areas whichmay enhance this field.Clostridium-based cancer
therapies are one of the most novel and promising methods
of cancer treatment currently being researched. The ability
of these Clostridium based modalities to selectively target
the microenvironment has provided a firm foundation for
which to build towards efficient, safe and effective cancer
treatments for the future and to improve the prognosis and
treatment of so many individual patients suffering from solid
tumours, relieving the burdens of patients, their families and
the healthcare systems.
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